about
Molecular pathways: targeting the TGF-β pathway for cancer therapyBreast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticityAllosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.Safety of contralateral submandibular gland sparing in locally advanced oropharyngeal cancers: A multicenter review.Synchronous primary carcinoma of breast and ovary versus ovarian metastases.Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities.A comprehensive comparative analysis of treatment modalities for sinonasal malignancies.The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma.Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy.Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer.Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer.Physician Bias in Prophylactic Cranial Irradiation Decision Making-An Opportunity for a Patient Decision Aid.Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer.Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer.Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database AnalysisCombination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4
P50
Q26849494-E5C90313-81BA-4A30-80B1-7896D0BDED10Q26851620-9D1FBEF5-2AE5-43D2-94DD-FF76F40712A6Q30409822-E849E3A5-9E79-4060-934E-084B4B23375DQ31079270-C37B9548-57B3-4C69-A48D-17E58B44AFEEQ34283431-743656F4-D306-48F5-ADA8-2B2F095EF8D5Q38284473-5969C4AB-4A23-4745-945B-02FCE02BA92AQ38406539-0EFA3AF3-DD4B-49E3-B61D-A847C591DC01Q38658058-DCDC9A46-ED45-4DF5-A3EF-C062BFFC6C3AQ38859817-0516E755-4D50-41CA-B56C-18B2F6F398BBQ38996722-8ED0E847-ABD3-468F-9993-E10E3172E3BFQ39309071-31837EA3-6FC3-4AF1-A0FE-4FA4E0A4AE9BQ40522836-28351B17-6F51-43EA-827F-02A0927BF8C5Q47900903-48778EE3-2EE2-4792-B664-F843DAB0788FQ52354103-0B1A6C95-3176-4500-BCBA-222F41C5955DQ53683482-FA4F182C-AF35-4E7E-9225-AD3E28F43A89Q64912640-54BCADC4-BC87-408A-ADD0-A02D9824DC20Q88399990-1839A824-5C1D-4370-B9A8-BB4DDD03B963Q92800681-68AFB42C-D4F4-47A2-94C4-3A870338EFF6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tyler P Robin
@ast
Tyler P Robin
@en
Tyler P Robin
@es
Tyler P Robin
@nl
type
label
Tyler P Robin
@ast
Tyler P Robin
@en
Tyler P Robin
@es
Tyler P Robin
@nl
prefLabel
Tyler P Robin
@ast
Tyler P Robin
@en
Tyler P Robin
@es
Tyler P Robin
@nl
P106
P31
P496
0000-0002-0211-5552